Alpha 2.0
Login Register
» Authors » B Paul Morgan

B Paul Morgan

Explore the profile of B Paul Morgan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 242
Citations 7396
Followers 0
Related Specialties
Allergy & Immunology
Neurology
Molecular Biology
Top 10 Co-Authors
Claire L Harris
Wioleta M Zelek
Timothy R Hughes
Masashi Mizuno
Santiago Rodriguez de Cordoba
Baalasubramanian Sivasankar
Svetlana Hakobyan
Rossen M Donev
Susan M Lea
Valeria Ramaglia
Published In
J Immunol
Mol Immunol
J Biol Chem
Immunology
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
11.
Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis
Evans R, Watkins L, Hawkins K, Santiago G, Demetriou C, Naughton M, et al.
Front Cell Neurosci . 2023 Apr; 17:1094106. PMID: 37032838
Background: The extent of cortical pathology is an important determinant of multiple sclerosis (MS) severity. Cortical demyelination and neurodegeneration are related to inflammation of the overlying leptomeninges, a more inflammatory...
12.
nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study
Chakraborty M, Rodrigues P, Watkins W, Hayward A, Sharma A, Hayward R, et al.
BMJ Open . 2023 Apr; 11(12):e050100. PMID: 37010923
Introduction: Diagnosing neonatal sepsis is heavily dependent on clinical phenotyping as culture-positive body fluid has poor sensitivity, and existing blood biomarkers have poor specificity.A combination of machine learning, statistical and...
13.
Complement receptor 1 is expressed on brain cells and in the human brain
Daskoulidou N, Shaw B, Torvell M, Watkins L, Cope E, Carpanini S, et al.
Glia . 2023 Feb; 71(6):1522-1535. PMID: 36825534
Genome wide association studies (GWAS) have highlighted the importance of the complement cascade in pathogenesis of Alzheimer's disease (AD). Complement receptor 1 (CR1; CD35) is among the top GWAS hits....
14.
Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies
Chen D, Kang T, Xu X, Xia W, Ye X, Wu Y, et al.
JCI Insight . 2023 Feb; 8(6). PMID: 36809299
Anti-CD36 Abs have been suggested to induce transfusion-related acute lung injury (TRALI) upon blood transfusion, particularly in Asian populations. However, little is known about the pathological mechanism of anti-CD36 Ab-mediated...
15.
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19
Siggins M, Davies K, Fellows R, Thwaites R, Baillie J, Semple M, et al.
Immunology . 2022 Sep; 168(3):473-492. PMID: 36175370
Complement, a critical defence against pathogens, has been implicated as a driver of pathology in COVID-19. Complement activation products are detected in plasma and tissues and complement blockade is considered...
16.
Complement dysregulation and Alzheimer's disease in Down syndrome
Veteleanu A, Pape S, Davies K, Kodosaki E, Hye A, Zelek W, et al.
Alzheimers Dement . 2022 Sep; 19(4):1383-1392. PMID: 36149090
Introduction: Down syndrome (DS) is associated with immune dysregulation and a high risk of early onset Alzheimer's disease (AD). Complement is a key part of innate immunity and driver of...
17.
Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
Lekova E, Zelek W, Gower D, Spitzfaden C, Osuch I, John-Morris E, et al.
Front Immunol . 2022 Sep; 13:968206. PMID: 36148231
Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG...
18.
Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
Seidel F, Kleemann R, van Duyvenvoorde W, van Trigt N, Keijzer N, van der Kooij S, et al.
Int J Mol Sci . 2022 Sep; 23(18). PMID: 36142647
Background: Chronic inflammation is an important driver in the progression of non-alcoholic steatohepatitis (NASH) and atherosclerosis. The complement system, one of the first lines of defense in innate immunity, has...
19.
Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models
Carpanini S, Torvell M, Bevan R, Byrne R, Daskoulidou N, Saito T, et al.
Acta Neuropathol Commun . 2022 Jul; 10(1):99. PMID: 35794654
Complement is involved in developmental synaptic pruning and pathological synapse loss in Alzheimer's disease. It is posited that C1 binding initiates complement activation on synapses; C3 fragments then tag them...
20.
Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex
Olesen H, Michailidou I, Zelek W, Vreijling J, Ruizendaal P, de Klein F, et al.
J Innate Immun . 2022 May; 15(1):16-36. PMID: 35551129
Damage and disease of nerves activates the complement system. We demonstrated that activation of the terminal pathway of the complement system leads to the formation of the membrane attack complex...